The biopharmaceutical manufacturing landscape is undergoing profound transformation driven by artificial intelligence and digital technologies. Industry leaders like Sanofi demonstrate how integrating AI and advanced analytics accelerates development, optimizes cell culture processes, and streamlines formulation, collectively reducing timelines and costs. Meanwhile, digital twin technology enables real-time process optimization, lowering costs and facilitating access to new markets, including low-income regions. Continuous biomanufacturing approaches mature, offering increased volumetric productivity, consistency, and reduced facility footprint. Together, these innovations herald a new era of smarter, more sustainable, and scalable bioprocessing critical for global healthcare needs.